"
Early Stage Triple Negative Breast Cancer Has Significantly Better Outcomes than More Advanced Disease: A Single Centre Retrospective Review"
written by Caroline Hamm, Swati Kulkarni, Rasna Gupta, Amin Kay, John Mathews, Khalid Hirmiz, Indryas Woldie, Akmal Ghafoor, Tarek Elfiki, Sindu Kanjeekal, Ming Pan, Kenneth Schneider, Junaid Yousuf, Mohammad Jarrar, Colvin Springer, Maher El-Masri,
published by
Journal of Cancer Therapy,
Vol.7 No.10, 2016
has been cited by the following article(s):
|
[1]
|
A prospective phase II clinical trial identifying the optimal regimen for carboplatin plus standard backbone of anthracycline and taxane-based chemotherapy in triple negative breast cancer
Medical Oncology,
2022
DOI:10.1007/s12032-021-01637-0
|
|
|
|
|
[2]
|
Are we overtreating stage I triple-negative breast cancer in Ontario? A population-based retrospective epidemiological analysis using the ICES database
Medical Oncology,
2022
DOI:10.1007/s12032-022-01829-2
|
|
|
|